Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevation Oncology, Inc. (ELEV) SEC filings archive provides a record of the company’s regulatory disclosures during its time as a publicly traded issuer and documents its transition to a private, wholly owned subsidiary of Concentra Biosciences, LLC. While Elevation Oncology’s common stock has been removed from listing on The Nasdaq Stock Market LLC and its registration under the Securities Exchange Act of 1934 has been terminated or suspended, its historical filings remain an important source of information about its operations, capital structure, and corporate transactions.
Investors and researchers can use Elevation Oncology’s annual reports on Form 10-K and quarterly reports on Form 10-Q (as referenced in company press releases) to review disclosures on research and development activities, general and administrative expenses, restructuring charges, and cash resources. These filings describe the company’s focus on selective cancer therapies, including its antibody-drug conjugate programs EO-3021, a Claudin 18.2 ADC, and EO-1022, a HER3 ADC in preclinical development, as discussed in its public communications.
Current reports on Form 8-K are particularly significant for understanding Elevation Oncology’s corporate evolution. A Form 8-K dated July 23, 2025 details the completion of a tender offer and merger with a subsidiary of Concentra Biosciences, through which Elevation Oncology became a wholly owned subsidiary and its common stock was converted into the right to receive cash and a contingent value right, subject to the terms of the merger agreement. The same filing explains the company’s request for Nasdaq to suspend trading and file a Form 25 to delist the shares, and notes the intention to file a Form 15 to terminate registration and suspend reporting obligations.
Subsequent regulatory steps are reflected in a Form 25 filed on July 23, 2025, which notifies the SEC of the removal of Elevation Oncology’s common stock from listing and registration on Nasdaq, and a Form 15 filed on August 4, 2025, which certifies the termination of registration of the common stock under Section 12(g) and the suspension of reporting duties under Sections 13 and 15(d). Together, these documents mark the end of Elevation Oncology’s status as a reporting company for its common stock.
On this filings page, AI-powered tools can help users quickly interpret complex regulatory language by summarizing key points from Forms 10-K, 10-Q, and 8-K, and by highlighting material events such as program discontinuations, restructuring activities, and the Concentra Biosciences acquisition. Historical insider and equity-related information referenced in merger-related disclosures, including the treatment of stock options, restricted stock units, and warrants, can also be reviewed through the underlying filings.
Nasdaq Stock Market LLC has filed Form 25 with the SEC to remove Elevation Oncology, Inc. (ELEV) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.
The notification, signed by AVP Tara Petta on 23 Jul 2025, states that Nasdaq has reasonable grounds to believe it satisfies all requirements for the filing and has complied with its own rules pursuant to Rule 12d2-2.
Once effective, the filing will strike the company’s sole listed security—its common stock—from Nasdaq’s official list and terminate its Section 12(b) registration.
Elevation Oncology (ELEV) has ceased to be a public company. On 23-Jul-2025, Concentra Biosciences closed its acquisition via a Section 251(h) short-form merger after its subsidiary accepted 67.09% of shares tendered at $0.36 cash per share plus one non-transferable contingent value right (CVR). All remaining shares were converted into the same consideration at the effective time.
Immediately following the closing, ELEV requested Nasdaq suspend trading and filed for delisting (Form 25) and deregistration (Form 15). All equity awards were treated per the merger terms: in-the-money options received cash for intrinsic value plus a CVR; out-of-the-money options were cancelled; RSUs vested and received cash and a CVR; 22.05 m warrants were cashed out at their Black-Scholes value.
The transaction triggered a change in control. All six legacy directors resigned and Concentra’s slate, led by Kevin Tang (CEO), assumed board and officer roles. Interim CEO/CFO Tammy Furlong was terminated without cause and entered a separation agreement providing 12 months base salary, 100% target bonus, an additional $600k cash payment and full accelerated vesting.
The certificate of incorporation and bylaws were amended and restated, completing ELEV’s transition to a wholly owned Concentra subsidiary.